1. Itch: an under‐recognized problem in psoriasis. (10th May 2019) Authors: Elewski, B.; Alexis, A.F.; Lebwohl, M.; Stein Gold, L.; Pariser, D.; Del Rosso, J.; Yosipovitch, G. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 33:Number 8(2019) Page Start: 1465 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. SAT0561 Persistence of Biologic Therapy in Psoriatic Disease: Results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). (9th June 2015) Authors: Menter, A.; Papp, K.; Krueger, G.G.; Augustin, M.; Kerdel, F.; Gooderham, M.; Goyal, K.; Fakharzadeh, S.; Langholff, W.; Sermon, J.; Calabro, S.; Pariser, D. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 863 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States. (11th October 2015) Authors: Kimball, A.B.; Schenfeld, J.; Accortt, N.A.; Anthony, M.S.; Rothman, K.J.; Pariser, D. Journal: British journal of dermatology Issue: Volume 173:Number 5(2015:Nov.) Page Start: 1183 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study. (6th May 2019) Authors: Bissonnette, R.; Maari, C.; Forman, S.; Bhatia, N.; Lee, M.; Fowler, J.; Tyring, S.; Pariser, D.; Sofen, H.; Dhawan, S.; Zook, M.; Zammit, D.J.; Usansky, H.; Denis, L.; Rao, N.; Song, T.; Pavel, A.B.; Guttman‐Yassky, E. Journal: British journal of dermatology Issue: Volume 181:Number 4(2019) Page Start: 733 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 苏金单抗持续用于治疗银屑病的疗效. (2nd January 2020) Authors: Augustin, M.; Thaci, D.; Eyerich, K.; Pinter, A.; Radtke, M.; Lauffer, F.; Mrowietz, U.; Gerdes, S.; Pariser, D.; Lebwohl, M.; Sieder, C.; Melzer, N.; Reich, K. Journal: British journal of dermatology Issue: Volume 182:Number 1(2020) Page Start: e39 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. The efficacy of secukinumab with continued use in the treatment of psoriasis. (2nd January 2020) Authors: Augustin, M.; Thaci, D.; Eyerich, K.; Pinter, A.; Radtke, M.; Lauffer, F.; Mrowietz, U.; Gerdes, S.; Pariser, D.; Lebwohl, M.; Sieder, C.; Melzer, N.; Reich, K. Journal: British journal of dermatology Issue: Volume 182:Number 1(2020) Page Start: e22 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Continued treatment with secukinumab is associated with high retention or regain of response. (17th July 2019) Authors: Augustin, M.; Thaci, D.; Eyerich, K.; Pinter, A.; Radtke, M.; Lauffer, F.; Mrowietz, U.; Gerdes, S.; Pariser, D.; Lebwohl, M.; Sieder, C.; Melzer, N.; Reich, K. Journal: British journal of dermatology Issue: Volume 182:Number 1(2020) Page Start: 67 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. The 2020 International Alliance for the Control of Scabies Consensus Criteria for the Diagnosis of Scabies. (29th March 2020) Authors: Engelman, D.; Yoshizumi, J.; Hay, R.J.; Osti, M.; Micali, G.; Norton, S.; Walton, S.; Boralevi, F.; Bernigaud, C.; Bowen, A.C.; Chang, A.Y.; Chosidow, O.; Estrada‐Chavez, G.; Feldmeier, H.; Ishii, N.; Lacarrubba, F.; Mahé, A.; Maurer, T.; Mahdi, M.M.A.; Murdoch, M.E. Journal: British journal of dermatology Issue: Volume 183:Number 5(2020) Page Start: 808 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. ASN002 demonstrates efficacy and improves inflammation in AD. (1st October 2019) Authors: Bissonnette, R.; Maari, C.; Forman, S.; Bhatia, N.; Lee, M.; Fowler, J.; Tyring, S.; Pariser, D.; Sofen, H.; Dhawan, S.; Zook, M.; Zammit, D.J.; Usansky, H.; Denis, L.; Rao, N.; Song, T.; Pavel, A.B.; Guttman‐Yassky, E. Journal: British journal of dermatology Issue: Volume 181:Number 4(2019) Page Start: e102 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study. (1st October 2019) Authors: Bissonnette, R.; Maari, C.; Forman, S.; Bhatia, N.; Lee, M.; Fowler, J.; Tyring, S.; Pariser, D.; Sofen, H.; Dhawan, S.; Zook, M.; Zammit, D.J.; Usansky, H.; Denis, L.; Rao, N.; Song, T.; Pavel, A.B.; Guttman‐Yassky, E. Journal: British journal of dermatology Issue: Volume 181:Number 4(2019) Page Start: 733 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗